オハイオにおける大うつ病性障害の臨床試験
オハイオ内の拠点で、大うつ病性障害に関する29件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder
- Patient Priority Clinical Sites LLC, Cincinnati
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/10/01更新 · NCT07573176Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- Patient Priority Clinical Sites LLC, Cincinnati
- The Ohio State University, Columbus
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/09/25更新 · NCT06559306Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Quest Therapeutics of Avon Lake, Avon Lake
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/25更新 · NCT05850689A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
- University of Cincinnati, Cincinnati
被験者募集中第3相
12歳〜17歳 · 全性別 · 2026/09/25更新 · NCT07227454Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
- Vanda Investigational Site, Cincinnati
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/09/24更新 · NCT06830044A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Independence
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/18更新 · NCT07105111A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
- Seaport Investigator Site, Independence
- Seaport Investigator Site, North Canton
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/09/14更新 · NCT07065240ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
- Neuro-Behavioral Clinical Research, North Canton
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/09/14更新 · NCT07284667A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- Insight Clinical Trials, Independence
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/09/08更新 · NCT07076407A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression
- Draig Clinical Site, Columbus
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/02更新 · NCT07610473Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
被験者募集中
22歳〜70歳 · 全性別 · 2026/08/28更新 · NCT06423430Positive Processes and Transition to Health (PATH)
- Case Western Reserve University, Cleveland
被験者募集中
18歳〜65歳 · 全性別 · 2026/08/19更新 · NCT06093906NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Mason
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/11更新 · NCT06911112A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- Cleveland Clinic, Cleveland
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/08/10更新 · NCT07592689Modulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains
- Lindner Center of Hope, Mason
被験者募集中第1/2相
18歳〜60歳 · 全性別 · 2026/08/03更新 · NCT06795451A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- Neuro-Behavioral Clinical Research, North Canton
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/08/03更新 · NCT06775379Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
被験者募集中第2相
18歳〜64歳 · 全性別 · 2026/08/03更新 · NCT06547489A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- Insight Clinical Trials LLC, Independence
被験者募集中第2相
18歳〜64歳 · 全性別 · 2026/07/27更新 · NCT07115329Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/24更新 · NCT06966401Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol
- Clinical Research Site, Cincinnati
- Clinical Research Site, Cincinnati
被験者募集中第3相
18歳〜65歳 · 全性別 · 2026/07/24更新 · NCT07484217A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety
- The Ohio State University Department of Psychiatry, Columbus
被験者募集中第2相
21歳〜65歳 · 全性別 · 2026/07/23更新 · NCT06820723A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- Quest Therapeutics of Avon /ID# 277550, Avon Lake
- OSU Psychiatry Department /ID# 277529, Columbus
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/06/15更新 · NCT07276997A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
- The Ohio State University, Columbus
- Neuro Behavioral Clinical Research, Inc., North Canton
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/05/11更新 · NCT06524830Improving Outcomes in Adolescent Inpatient Depression With Deep Transcranial Magnetic Stimulation
- Cincinnati Childrens Hospital Medical Center, Cincinnati
被験者募集中
14歳〜18歳 · 全性別 · 2026/02/11更新 · NCT07217444Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Autobahn Site #109, Beachwood
被験者募集中第2相
18歳〜65歳 · 全性別 · 2026/01/20更新 · NCT06633016Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Neurocrine Clinical Site, Avon Lake
被験者募集中第3相
18歳以上 · 全性別 · 2025/10/29更新 · NCT06786624Mechanisms of Rumination Change in Adolescent Depression
- Nationwide Children's Hospital, Columbus
- The Ohio State University, Columbus
被験者募集中
14歳〜17歳 · 全性別 · 2025/08/11更新 · NCT03859297A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- Clinical Research Site, Cincinnati
被験者募集中第4相
18歳〜65歳 · 全性別 · 2025/01/23更新 · NCT06223880ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。